Connect with us

Business

Mydecine Innovations Group (OTCMKTS: MYCOF) Engages JBN Partners and Attains AI Breakthrough in psychedelics Drug Development

Published

on

Mydecine Innovations Group (OTCMKTS: MYCOF) has announced the engagement of JBN Partners LLC to boost public awareness and interest in the company, its products, and its management.

Mydecine hires public relations firm to enhance awareness 

JBN will achieve this by coordinating specific investor relations and company financial public relations with the investor community, general public, and financial media. The JBN services agreement has six months and a total payment worth of $150,000.

Mydecine was created in 2020 to believe that there is a major unmet demand and a scarcity of innovation in the behavioral health and treatment fields. The company is committed to rapidly discovering novel therapies to treat PTSD, addiction, anxiety, depression, and other mental health conditions. The business approach of Mydecine Innovations Group includes clinical trials and data outcomes, scientific, technology, and regulatory knowledge, and a focus on psychedelic treatment supported by additional innovative compounds with distinct therapeutic potential.

Notably, Mydecine seeks to accelerate the development of novel medicines throughout its platforms by partnering with some of the world’s greatest authorities linked by best practices to effectively treat and ultimately change the way mental disorders are treated. Its mission is to close the gap between what the present cognitive healthcare system offers and what patients require.

Mydecine produces target-based models of psychedelic serotonin receptor 5-HT2A

The company has produced a target-based simulation of the iconic psychedelic serotonin receptor 5-HT2A for use in its AI-driven drug development program, the company said today. The new methodology will allow them to quickly screen billions of compounds to see which compounds are more likely to improve binding affinity, allowing them to continue developing better 2nd  and 3rd generation psychedelic chemicals for medical usage.

Mydecine is positioned to develop therapeutic enhancements more cost-effectively and efficiently than its competitors by focusing its drug discovery efforts on machine learning (ML) and artificial intelligence (AI). AI and ML help the company to drastically cut or reduce the manual efforts undergone to identify potential drug improvements.

*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.